Every Form 4 that Integra LifeSciences Holdings (IART) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow IART and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full IART filings page.
INTEGRA LIFESCIENCES HOLDINGS CORP (IART) reported that executive vice president and chief human resources officer Chantal Veillon-Berteloot had 1,455 shares of Common Stock disposed of on September 1, 2026 as a payment of exercise price or tax liability by delivering or withholding securities. The shares were treated as a non-derivative transaction at a reported price of $16.62 per share, and she now holds 20,772 shares directly. No Rule 10b5-1 trading plan is indicated for this transaction.
INTEGRA LIFESCIENCES HOLDINGS CORP senior vice president and principal accounting officer Jeffrey Mosebrook reported a tax-related share disposition. On this Form 4, 937 shares of common stock were delivered at $17.89 per share to satisfy tax obligations, leaving him with 34,516 directly held shares.
Singh Harvinder reported acquisition or exercise transactions in this Form 4 filing.
Integra LifeSciences EVP & President, SS Harvinder Singh received a grant of 5,590 restricted stock units (RSUs). The award was made under the Integra LifeSciences Holdings Corporation Fifth Amended and Restated 2003 Equity Incentive Plan.
Each RSU represents a contingent right to receive one share of common stock. The RSUs will vest in three equal annual installments on the first, second, and third anniversaries of the grant date, subject to his continued service. Following this grant, Singh holds 68,883 RSUs directly.
DAVIS ROBERT T. JR. reported acquisition or exercise transactions in this Form 4 filing.
Integra LifeSciences Holdings Corp executive Robert T. Davis Jr., EVP & President, TR&DT, received a grant of 11,180 restricted stock units (RSUs) tied to the company’s common stock. These RSUs were awarded under the company’s Fifth Amended and Restated 2003 Equity Incentive Plan as part of equity compensation.
Each RSU represents a contingent right to receive one share of common stock and will vest in full on the second anniversary of the grant date, assuming he continues in service through that date. Following this award, Davis directly holds 54,530 RSUs in total.
INTEGRA LIFESCIENCES HOLDINGS CORP Executive Vice President and Chief Financial Officer Lea Daniels Knight reported a routine tax-related share disposition. On this Form 4, 5,226 shares of common stock were withheld at $18.05 per share to satisfy tax obligations, leaving her with 45,263 directly held shares.
INTEGRA LIFESCIENCES HOLDINGS CORP executive Michael J. McBreen, EVP & Chief Commercial Officer, received equity awards as part of his compensation. He was granted 31,909 restricted stock units and a non-qualified stock option for 60,372 shares at an exercise price of $15.67 per share. Both awards vest in three equal annual installments starting on the first anniversary of the grant date, contingent on his continued service. Following the RSU grant, he holds 124,017 shares of common stock directly.
Integra LifeSciences Holdings Corp President and CEO Stuart Essig received significant equity awards as compensation. On 6/1/2026, he was granted 365,297 restricted stock units, each representing one share of common stock, and 705,468 non-qualified stock options with a conversion price of $15.6700 per share.
The option award consists of 482,976 options granted under his employment agreement and 222,492 options granted at the Compensation Committee’s discretion. The RSU award consists of 255,265 RSUs under the employment agreement and 110,032 RSUs granted by the Compensation Committee.
All awards were granted under the company’s equity incentive plan and will vest one-third on the first anniversary of 5/1/2026, then in monthly installments over the following twenty-four months, subject to his continued service. These are grants/awards, not open-market purchases or sales.
HILL BARBARA B reported acquisition or exercise transactions in this Form 4 filing.
INTEGRA LIFESCIENCES HOLDINGS CORP reported that director Barbara B. Hill received two stock awards of the company’s Common Stock on May 7, 2026. She was granted 17,700 shares and 6,638 shares at a price of $0.00 per share as equity compensation. Following these awards, she directly owns 151,191 shares, and an additional 36,350 shares are held indirectly by a trust.
Integra LifeSciences director Keith Bradley reported routine equity compensation and related tax withholding. He received 17,700 Restricted Stock Units (RSUs) on May 7, 2026 under Integra’s Fifth Amended and Restated 2003 Equity Incentive Plan, with each RSU representing a right to one share of common stock and vesting in full on the one-year anniversary of the grant date. To cover tax obligations, 882 shares of common stock were withheld at $13.92 per share. Following these transactions, Bradley directly holds 88,254 shares of Integra common stock.
Clay Shaundra reported acquisition or exercise transactions in this Form 4 filing.
INTEGRA LIFESCIENCES HOLDINGS CORP director Shaundra Clay received a grant of 17,700 restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of IART common stock under the company’s Fifth Amended and Restated 2003 Equity Incentive Plan.
The RSUs vest in full on the one-year anniversary of the May 7, 2026 grant date. Clay elected to defer receipt of the underlying shares, which will be delivered in a single lump sum in the calendar year following the year her service on the Board ends, unless she elected a later year.
GRAVES JEFFREY A reported acquisition or exercise transactions in this Form 4 filing.
INTEGRA LIFESCIENCES HOLDINGS CORP director Jeffrey A. Graves received a grant of 17,700 Restricted Stock Units (RSUs). The award was made on May 7, 2026 under the company’s Fifth Amended and Restated 2003 Equity Incentive Plan, at a grant price of $0.00 per unit.
Each RSU represents a contingent right to receive one share of Integra LifeSciences common stock, so the grant covers 17,700 underlying shares. The RSUs vest in full on the one-year anniversary of the grant date of May 7, 2026. Following this grant, Graves holds 17,700 RSUs directly.
Lo Renee Wonlai reported acquisition or exercise transactions in this Form 4 filing.
INTEGRA LIFESCIENCES HOLDINGS CORP director Renee Wonlai Lo received a grant of 17,700 restricted stock units (RSUs) as equity compensation. Each RSU represents a contingent right to receive one share of IART common stock. The RSUs vest in full on the one-year anniversary of the grant date of May 7, 2026, and this award brings her reported RSU holdings to 17,700 units.
SCHADE CHRISTIAN S reported acquisition or exercise transactions in this Form 4 filing.
INTEGRA LIFESCIENCES HOLDINGS CORP director Christian S. Schade received a grant of 17,700 restricted stock units (RSUs) tied to the company’s common stock. The award was made at no cash cost under Integra’s Fifth Amended and Restated 2003 Equity Incentive Plan.
The RSUs vest in full on the one-year anniversary of the grant date of May 7, 2026. Schade elected to defer delivery of the underlying shares until a lump-sum payment is made in the calendar year after his service on the Board ends, or a later year he elected. Following this grant, he holds 17,700 RSUs directly from this award.
INTEGRA LIFESCIENCES executive Harvinder Singh, EVP & President, International, reported compensation-related equity activity. On March 11, 2026, he received a grant of 60,865 restricted stock units, which will vest 33%, 33% and 34% on the first, second and third anniversaries of the March 11, 2026 grant date.
Several earlier restricted stock unit awards vested on their second and third anniversaries, leading to the conversion of 20,138 units into common stock over March 10–11, 2026. To cover tax obligations, a total of 6,652 common shares were withheld at prices of $9.55 and $9.61 per share.
After these transactions, Singh directly holds 35,422 shares of common stock. The filing reflects routine vesting and tax withholding rather than open-market buying or selling.
INTEGRA LIFESCIENCES HOLDINGS CORP executive Michael J. McBreen, EVP & President, CSS, received a grant of 92,108 restricted stock units that will vest 33% on the first and second anniversaries and 34% on the third anniversary of the 3/11/2026 grant date.
To cover tax obligations, he disposed of 2,354 and 7,247 shares of common stock at $9.55 and $9.61 per share through tax-withholding transactions, not open-market sales. Following these transactions, he directly holds 60,743 common shares and the new 92,108 RSUs.
Integra LifeSciences executive Robert T. Davis Jr., EVP & President, TT, received a grant of 43,350 restricted stock units on March 11, 2026. These RSUs vest 33% on the first and second anniversaries and 34% on the third anniversary of the grant date.
To cover tax obligations, 8,487 shares of common stock were disposed of at $9.61 per share on March 11, 2026, and 687 shares at $9.55 per share on March 10, 2026, both classified as tax-withholding transactions rather than open-market sales. After these transactions, Davis directly holds 66,387 shares of common stock and 43,350 RSUs.
INTEGRA LIFESCIENCES HOLDINGS CORP senior vice president and principal accounting officer Jeffrey Mosebrook received a grant of 15,957 restricted stock units on March 11, 2026. These RSUs will vest 33% on the first and second anniversaries of the grant date and 34% on the third anniversary.
To cover tax liabilities, 341 common shares at $9.55 per share on March 10, 2026 and 806 common shares at $9.61 per share on March 11, 2026 were withheld. Following these transactions, Mosebrook directly owns 35,453 common shares and holds 15,957 RSUs.
INTEGRA LIFESCIENCES HOLDINGS CORP EVP & Chief Financial Officer Lea Daniels Knight reported a compensation-related equity grant and routine tax withholding. She received 111,179 restricted stock units linked to common stock, which vest 33% on the first and second anniversaries of the March 11, 2026 grant date and 34% on the third anniversary.
On the same date, 8,089 shares of common stock were disposed of at $9.61 per share to cover tax obligations, and she now directly holds 50,489 common shares.
INTEGRA LIFESCIENCES HOLDINGS CORP executive Chantal Veillon-Berteloot, EVP & CHRO, reported an equity compensation grant and related tax withholding. She received 41,783 restricted stock units, each representing one share of common stock. The award will vest 33% on the first and second anniversaries and 34% on the third anniversary of the 3/11/2026 grant date.
On the same date, 5,420 shares of common stock were disposed of at $9.61 per share to satisfy tax liabilities through share withholding, rather than an open-market sale. Following these transactions, Veillon-Berteloot directly owns 22,227 shares of common stock.
Poul Mojdeh reported acquisition or exercise transactions in this Form 4 filing.
INTEGRA LIFESCIENCES HOLDINGS CORP reported that President & CEO Poul Mojdeh received a grant of 343,393 restricted stock units tied to common stock. The award vests in three equal annual installments on the first, second, and third anniversaries of the March 11, 2026 grant date.
The units are structured as deferred compensation, to be delivered within 30 days after the first business day following six months after her separation of service. Vesting may accelerate if employment ends due to death, disability, or a qualifying termination within 24 months after a change in control. Following this grant, her reported holdings in this RSU award total 445,691 units.
Hutchinson Michael Damon reported acquisition or exercise transactions in this Form 4 filing.
INTEGRA LIFESCIENCES HOLDINGS CORP executive Michael Damon Hutchinson, EVP and Chief Legal Officer, received a grant of 70,305 restricted stock units tied to common stock. This award will vest 33% on the first and second anniversaries and 34% on the third anniversary of the March 11, 2026 grant date, increasing his directly held RSU position to 159,911 units.
Integra LifeSciences Holdings Corp reported an equity grant to executive officer Michael Damon Hutchinson, EVP, Chief Legal Officer & Secretary. On 02/02/2026, he received 89,606 restricted stock units at a price of $0 per unit, held as a direct interest.
The filing states that this restricted stock unit award will vest 100% on the second anniversary of the grant date of 02/02/2026, meaning the award is fully time‑based and contingent on continued service through that future vesting date.
Integra LifeSciences Holdings Corp President & CEO Mojdeh Poul reported routine equity compensation activity. On January 6, 2026, 848 and 542 shares of common stock were acquired at $0 per share upon the vesting and settlement of corresponding restricted stock units.
On the same date, 848 and 542 common shares were disposed of at $13.13 per share in transactions coded "F", reflecting shares withheld or sold to cover taxes. Following these transactions, the report shows no directly held common stock, while Ms. Poul continues to hold restricted stock unit awards, with post-transaction amounts reported as 102,840 and 102,298 units in two separate grants. A footnote explains that these awards vest in three equal annual installments starting January 6, 2026 and are scheduled for deferred delivery after her separation from service.
Integra LifeSciences (IART) director Jeffrey Alan Graves reported an open‑market purchase of 9,000 shares on 11/05/2025 at $11.35 per share.
Following the transaction, he beneficially owns 41,086 shares, held directly. The report was filed as a Form 4 and signed by an attorney‑in‑fact.
Integra LifeSciences (IART) reported an insider equity event. EVP & President, International Harvinder Singh vested 11,965 restricted stock units on 10/12/2025, which settled into common stock. To cover taxes, 3,281 shares were withheld at $13.34, and the reporting person retained 8,684 shares from the vesting. Following these transactions, direct beneficial ownership stood at 21,936 common shares.
The RSU award vested in full on the third anniversary of its grant date (10/12/2022). Derivative securities beneficially owned following the event were 22,566 RSUs.